Latest Information Update: 05 Sep 2007
At a glance
- Originator Chong Kun Dang
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Apr 2003 No development reported - Preclinical for Cancer in South Korea (unspecified route)
- 06 Jun 2000 New profile
- 06 Jun 2000 Preclinical development for Cancer in South Korea (Unknown route)